Bristol Myers Squibb signed a multiyear research and discovery collaboration with Harbour BioMed to accelerate antibody discovery and development, with potential payments that can reach $1.1 billion. The agreement will fund Harbour’s discovery efforts and grant BMS options on resulting programs. The deal underlines continued Big Pharma demand for external antibody discovery engines and the premium being paid for platforms that can speed target‑to‑clinic timelines. For Harbour, the pact provides near‑term capital and validation of its discovery capabilities; for BMS it expands antibody R&D capacity without enlarging in‑house discovery teams.